Pharmacy EBIT fell 25% as COVID tail faded; net cash flipped to net debt

The prior comparable included Community Health, which contributed NZ$106.5m of revenue and NZ$6.6m of segment profit in HY23 and is absent in HY24. On a continuing-operations basis, management states revenue rose 1% and group operating profit fell 17% to NZ$14.9m, with Pharmacy operating profit down 25% as higher-margin COVID-19 activity normalised.

The balance sheet moved alongside the earnings step-down. Operating cash flow fell 35.0% to NZ$18.8m, pre-lease FCF of NZ$15.6m sits at the bottom of the three-period range (mean NZ$21.5m), cash on hand fell from NZ$43.6m to NZ$18.5m, and gross borrowings rose 26.7% to NZ$31.4m. The group moved from net cash of NZ$18.9m to net debt of NZ$12.9m.

1. Pharmacy segment margin contracted from 6.45% to 4.77% on essentially flat revenue (NZ$181.5m versus NZ$179.5m), and Medical margin contracted from 13.56% to 10.68%. Stripping out Community Health, the continuing business has held revenue but lost roughly a quarter of Pharmacy segment profit. This matters because the 4.77% Pharmacy margin is likely the new baseline, not a one-off.

2. Balance sheet flexibility narrowed. A NZ$25.2m fall in cash, a NZ$6.6m rise in borrowings, and inventory days at 23.8 (above the historical range of 16.6–23.4) all moved in the wrong direction at once. ROE fell to 3.4% from 6.5%, sitting at the lower edge of the recent range. This matters because the company no longer has the cushion it carried into HY23 to absorb earnings volatility while continuing to distribute.

3. The payout ratio looks stretched against earnings but not against cash. At 63.9%, the NPAT payout is above the historical range of 44.3–63.6%; against pre-lease FCF the 23.0% payout sits within the historical range. The interim of 2.5cps is therefore covered by current cash generation but leaves less retention if depressed earnings persist.

The seasonality context is distorted: HY23 was 71.9% of FY23 revenue but only 25.1% of FY23 NPAT because the FY23 full year included a disposal gain that lifted reported NPAT by 89% to NZ$45.2m. That makes the H1 NPAT share a poor anchor for forecasting H2 underlying earnings.

What the release supports is roughly flat continuing-operations revenue, structural margin compression in Pharmacy from COVID-19 service normalisation, and a tighter balance sheet. What it does not support is a clear view of where Pharmacy or Medical margins stabilise, or whether the elevated inventory level is structural.

The lost contribution is reduced higher-margin COVID-19 activity, which is unlikely to return, so the underlying earnings base has reset rather than absorbed a one-off. The 27.1% effective tax rate is below the historical mean of 28.5% and slightly flattered NPAT, but PBT and NPAT growth differ by only 0.2 percentage points so tax did not distort the read.

Cash quality is the weaker line. FCF-to-NPAT conversion of 277.7% looks supportive in isolation, but only because NPAT halved; absolute pre-lease FCF at NZ$15.6m is the lowest in the supplied historical range. Inventory days rising to 23.8 alongside a 1.3% capex intensity (versus 0.9% prior) absorbed cash that previously flowed to the balance sheet. The combination of falling reported earnings, weaker absolute cash generation, and a swing into net debt means more of this result is balance-sheet-assisted to maintain the distribution than the headline FCF cover suggests.

This briefing cannot assess the valuation implication without an updated share price and analyst forecasts for FY24 continuing-operations earnings.